US EditionSaudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration
SUFFOLK COUNTY, MASSACHUSETTS, JUN 20 – 64x Bio and Fauna Bio introduced platforms to reduce gene therapy manufacturing costs and accelerate AI-driven drug target discovery, improving scalability and patient reach, company data show.
6 Articles
6 Articles
Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia has concluded its landmark debut at the BIO International Convention 2025, having signed more than a dozen partnerships, launched a national biotech accelerator program with Biolabs and established the Kingdom as a global hub for life sciences. Over four days, Saudi delegates showcased an ecosystem ready for collaboration across scientific discovery, clinical research, and advanced therapeut…
Caregen Achieves Milestones at BIO USA 2025
Caregen's independent booth at BIO USA 2025 (Photo courtesy of Caregen) Caregen, a biotech company specializing in synthetic peptides, has announced the successful completion of numerous global partnering meetings at its standalone booth during the world’s largest biotechnology event, BIO International Convention 2025 (BIO USA), held in Boston, USA. Since 2019, Caregen has been participating annually with an independent booth, continuously expan…
The 2025 BIO International Convention - Data Intelligence
Much of the attention of the biotech industry has been focused on the city of Boston this week as the annual BIO International Convention hit town. BIO is the world’s largest partnering conference for the biopharma industry and thousands of innovators, out-licensors, venture capitalists, top pharma dealmakers, thought leaders and more than a few politicians gathered for three days of meetings, presentations, and networking. In this week’s episo…
At BIO, Companies Launch New Products for AAV Manufacturing, AI Drug Discovery
At this year’s BIO International Convention, held June 16–19 in Boston, MA, two companies, 64x Bio and Fauna Bio, introduced new products aimed at improving therapy delivery and identifying novel drug targets for a range of human diseases, respectively. For its part, 64x Bio launched AAV Apex suite, a product designed to address bottlenecks in gene therapy manufacturing. Through the suite, the company provides suspension-adapted HEK293 cell l…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
